for almost a decade; however, low mutation detection rate and cost have hindered uptake.
This study sought to identify clinical variables that can predict probands with hypertrophic
cardiomyopathy in whom a pathogenic mutation will be identified. Methods Probands
attending specialized cardiac genetic clinics across Australia over a 10-year period (2002–
2011), who met clinical diagnostic criteria for hypertrophic cardiomyopathy and who …